Clear bull flag for CLRB on higher timeframesCLRB is poised for some upward movement within a descending broadening wedge on the higher timeframes. This forms the flag on a larger bullish bull flag.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.7121 USD
−42.77 M USD
0.00 USD
40.04 M
About Cellectar Biosciences, Inc.
Sector
CEO
James V. Caruso
Headquarters
Florham Park
Website
Founded
1996
FIGI
BBG000G9WFQ5
Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124 which could detect tumors and metastases in a broad range of cancers and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded in June 1996 and is headquartered in Florham Park, NJ.
CLRB Cellectar Biosciences Options Ahead of EarningsAnalyzing the options chain and the chart patterns of CLRB Cellectar Biosciences prior to the earnings report this week,
I would consider purchasing the 5usd strike price in the money Puts with
an expiration date of 2024-4-19,
for a premium of approximately $1.15.
If these options prove to be profit
RiskMastery's Breakout Stocks - CLRB EditionWelcome to RiskMastery's Breakout Stocks - Stocks with breakout potential .
In this edition, we'll be looking at NASDAQ:CLRB ...
I believe this code is at a point of potential volatility.
If price can hold above $3.50 ... Bullish potential may be unlocked.
My key upside targets includ
$CLRB can rise in the next daysContextual immersion trading strategy idea.
Cellectar Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer.
The demand for shares of the company looks higher than the supply.
This and othe
Long Upside but needs more volume. They have an upside price target of 5.40. There a few resistance points but I will probably set my long term target at the top green marker on the chart. A downfall from time to time is the volume on this stock.
Cellectar Biosciences, Inc., a clinical stage biopharmaceutical company, focuses o
CLRB Gap Down / Double Bottom Weekly - *ON HIGH ALERT*This would could be 60-120% gianer if you get in correctly. I am waiting maybe tomorrow or day just depends. I want to know we have a bottom here. LONG.
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of CLRB is 0.2350 USD — it has decreased by −1.26% in the past 24 hours. Watch Cellectar Biosciences, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Cellectar Biosciences, Inc. stocks are traded under the ticker CLRB.
CLRB stock has fallen by −9.62% compared to the previous week, the month change is a −85.40% fall, over the last year Cellectar Biosciences, Inc. has showed a −91.26% decrease.
We've gathered analysts' opinions on Cellectar Biosciences, Inc. future price: according to them, CLRB price has a max estimate of 13.00 USD and a min estimate of 1.00 USD. Watch CLRB chart and read a more detailed Cellectar Biosciences, Inc. stock forecast: see what analysts think of Cellectar Biosciences, Inc. and suggest that you do with its stocks.
CLRB reached its all-time high on Aug 12, 2005 with the price of 13,678,200.0000 USD, and its all-time low was 0.2240 USD and was reached on Dec 19, 2024. View more price dynamics on CLRB chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
CLRB stock is 8.48% volatile and has beta coefficient of 2.68. Track Cellectar Biosciences, Inc. stock price on the chart and check out the list of the most volatile stocks — is Cellectar Biosciences, Inc. there?
Today Cellectar Biosciences, Inc. has the market capitalization of 9.70 M, it has decreased by −14.02% over the last week.
Yes, you can track Cellectar Biosciences, Inc. financials in yearly and quarterly reports right on TradingView.
Cellectar Biosciences, Inc. is going to release the next earnings report on Mar 4, 2025. Keep track of upcoming events with our Earnings Calendar.
CLRB earnings for the last quarter are −0.40 USD per share, whereas the estimation was −0.33 USD resulting in a −21.21% surprise. The estimated earnings for the next quarter are −0.35 USD per share. See more details about Cellectar Biosciences, Inc. earnings.
Cellectar Biosciences, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
CLRB net income for the last quarter is −14.66 M USD, while the quarter before that showed −919.37 K USD of net income which accounts for −1.50 K% change. Track more Cellectar Biosciences, Inc. financial stats to get the full picture.
No, CLRB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 22, 2024, the company has 23.00 employees. See our rating of the largest employees — is Cellectar Biosciences, Inc. on this list?
Like other stocks, CLRB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Cellectar Biosciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Cellectar Biosciences, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Cellectar Biosciences, Inc. stock shows the strong sell signal. See more of Cellectar Biosciences, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.